TD Cowen Maintains Buy Rating for AstraZeneca (AZN) Amid Strong Analyst Consensus
TD Cowen analyst Steve Scala has reaffirmed his “Buy” rating for AstraZeneca (AZN), signaling continued confidence in the pharmaceutical giant’s market potential. The latest update comes after AstraZeneca’s shares closed at $81.19 last Friday, reflecting solid performance in a competitive sector. As the pharmaceutical industry remains dynamic, Scala’s endorsement of the stock underscores AstraZeneca’s strong…